featured
Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Refractory EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study
J. Clin. Oncol 2024 Jun 10;[EPub Ahead of Print], NB Leighl, H Akamatsu, SM Lim, Y Cheng, AR Minchom, ME Marmarelis, RE Sanborn, J Chih-Hsin Yang, B Liu, T John, B Massutí, AI Spira, SH Lee, J Wang, J Li, C Liu, S Novello, M Kondo, M Tamiya, E Korbenfeld, M Moskovitz, JY Han, M Alexander, R Joshi, E Felip, PJ Voon, P Danchaivijitr, PC Hsu, FJ Silva Melo Cruz, T Wehler, L Greillier, E Teixeira, D Nguyen, JK Sabari, A Qin, D Kowalski, MA Nahit Şendur, J Xie, D Ghosh, A Alhadab, N Haddish-Berhane, PL Clemens, P Lorenzini, RB Verheijen, M Gamil, JM Bauml, M Baig, A PassaroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.